|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jung KW, Won YJ, Oh CM, Kong HJ, Lee DH
and Lee KH; Community of Population-Based Regional Cancer
Registries: Cancer statistics in Korea: Incidence, mortality,
survival, and prevalence in 2014. Cancer Res Treat. 49:292–305.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Fedewa SA, Miller KD,
Goding-Sauer A, Pinheiro PS, Martinez-Tyson D and Jemal A: Cancer
statistics for Hispanics/Latinos, 2015. CA Cancer J Clin.
65:457–480. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Janssen S, Käsmann L, Rudat V and Rades D:
Stereotactic body radiation therapy (SBRT) for recurrent non-small
cell lung cancer (NSCLC). Anticancer Res. 36:825–828.
2016.PubMed/NCBI
|
|
6
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Santarpia M, Altavilla G, Salazar MF,
Magri I, Pettineo G, Benecchi S and Rosell R: Tyrosine kinase
inhibitors for non-small-cell lung cancer: Finding patients who
will be responsive. Expert Rev Respir Med. 5:413–424. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guo G, Gong K, Wohlfeld B, Hatanpaa KJ,
Zhao D and Habib AA: Ligand-independent EGFR signaling. Cancer Res.
75:3436–3441. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sholl LM, Yeap BY, Iafrate AJ,
Holmes-Tisch AJ, Chou YP, Wu MT, Goan YG, Su L, Benedettini E, Yu
J, et al: Lung adenocarcinoma with EGFR amplification has distinct
clinicopathologic and molecular features in never-smokers. Cancer
Res. 69:8341–8348. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kong FM, Ten Haken RK, Schipper M, Frey
KA, Hayman J, Gross M, Ramnath N, Hassan KA, Matuszak M, Ritter T,
et al: Effect of midtreatment PET/CT-adapted radiation therapy with
concurrent chemotherapy in patients with locally advanced
non-small-cell lung cancer: A phase 2 clinical trial. JAMA Oncol.
3:1358–1365. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Levine M and Julian J: Imaging: PET-CT
imaging in non-small-cell lung cancer. Nat Rev Clin Oncol.
6:619–620. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Na II, Byun BH, Kang HJ, Cheon GJ, Koh JS,
Kim CH, Choe DH, Ryoo BY, Lee JC, Lim SM, et al:
18F-fluoro-2-deoxyglucose uptake predicts clinical
outcome in patients with gefitinib-treated non-small cell lung
cancer. Clin Cancer Res. 14:2036–2041. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kobe C, Scheffler M, Holstein A, Zander T,
Nogova L, Lammertsma AA, Boellaard R, Neumaier B, Ullrich RT,
Dietlein M, et al: Predictive value of early and late residual
18F-fluorodeoxyglucose and
18F-fluorothymidine uptake using different SUV
measurements in patients with non-small-cell lung cancer treated
with erlotinib. Eur J Nucl Med Mol Imaging. 39:1117–1127. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Horiuchi C, Tsukuda M, Taguchi T, Ishiguro
Y, Okudera K and Inoue T: Correlation between FDG-PET findings and
GLUT1 expression in salivary gland pleomorphic adenomas. Ann Nucl
Med. 22:693–698. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Grabellus F, Nagarajah J, Bockisch A,
Schmid KW and Sheu SY: Glucose transporter 1 expression, tumor
proliferation, and iodine/glucose uptake in thyroid cancer with
emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med.
37:121–127. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Prata C, Maraldi T, Fiorentini D, Zambonin
L, Hakim G and Landi L: Nox-generated ROS modulate glucose uptake
in a leukaemic cell line. Free Radic Res. 42:405–414. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Prata C, Maraldi T, Zambonin L, Fiorentini
D, Hakim G and Landi L: ROS production and Glut1 activity in two
human megakaryocytic cell lines. Biofactors. 20:223–233. 2004.
View Article : Google Scholar
|
|
18
|
Lo YM: The amplification refractory
mutation system. Methods Mol Med. 16:61–69. 1998.PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−ΔΔC(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
20
|
Weyemi U, Lagente-Chevallier O, Boufraqech
M, Prenois F, Courtin F, Caillou B, Talbot M, Dardalhon M, Al
Ghuzlan A, Bidart JM, et al: ROS-generating NADPH oxidase NOX4 is a
critical mediator in oncogenic H-Ras-induced DNA damage and
subsequent senescence. Oncogene. 31:1117–1129. 2012. View Article : Google Scholar :
|
|
21
|
Waris G, Turkson J, Hassanein T and
Siddiqui A: Hepatitis C virus (HCV) constitutively activates STAT-3
via oxidative stress: Role of STAT-3 in HCV replication. J Virol.
79:1569–1580. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kodama R, Kato M, Furuta S, Ueno S, Zhang
Y, Matsuno K, Yabe-Nishimura C, Tanaka E and Kamata T:
ROS-generating oxidases Nox1 and Nox4 contribute to oncogenic
Ras-induced premature senescence. Genes Cells. 18:32–41. 2013.
View Article : Google Scholar
|
|
23
|
Lara-Guerra H, Waddell TK, Salvarrey MA,
Joshua AM, Chung CT, Paul N, Boerner S, Sakurada A, Ludkovski O, Ma
C, et al: Phase II study of preoperative gefitinib in clinical
stage I non-small-cell lung cancer. J Clin Oncol. 27:6229–6236.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sunaga N, Tomizawa Y, Yanagitani N, Iijima
H, Kaira K, Shimizu K, Tanaka S, Suga T, Hisada T, Ishizuka T, et
al: II prospective study of the efficacy of gefitinib for the
treatment of stage III/IV non-small cell lung cancer with EGFR
mutations, irrespective of previous chemotherapy. Lung Cancer.
56:383–389. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu A, Han A, Zhu H, Ma L, Huang Y, Li M,
Jin F, Yang Q and Yu J: The role of metabolic tumor volume (MTV)
measured by [18F] FDG PET/CT in predicting EGFR gene
mutation status in non-small cell lung cancer. Oncotarget.
8:33736–33744. 2017.PubMed/NCBI
|
|
26
|
Guan J, Xiao NJ, Chen M, Zhou WL, Zhang
YW, Wang S, Dai YM, Li L, Zhang Y, Li QY, et al: 18F-FDG
uptake for prediction EGFR mutation status in non-small cell lung
cancer. Medicine (Baltimore). 95:e44212016. View Article : Google Scholar
|
|
27
|
Minamimoto R, Jamali M, Gevaert O,
Echegaray S, Khuong A, Hoang CD, Shrager JB, Plevritis SK, Rubin
DL, Leung AN, et al: Prediction of EGFR and KRAS mutation in
non-small cell lung cancer using quantitative 18F
FDG-PET/CT metrics. Oncotarget. 8:52792–52801. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Takamochi K, Mogushi K, Kawaji H,
Imashimizu K, Fukui M, Oh S, Itoh M, Hayashizaki Y, Ko W, Akeboshi
M, et al: Correlation of EGFR or KRAS mutation status with
18F-FDG uptake on PET-CT scan in lung adenocarcinoma.
PLoS One. 12:e01756222017. View Article : Google Scholar
|
|
29
|
Caicedo C, Garcia-Velloso MJ, Lozano MD,
Labiano T, Vigil Diaz C, Lopez-Picazo JM, Gurpide A, Zulueta JJ,
Richter Echevarria JA and Perez Gracia JL: Role of
[18F]FDG PET in prediction of KRAS and EGFR mutation
status in patients with advanced non-small-cell lung cancer. Eur J
Nucl Med Mol Imaging. 41:2058–2065. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yoshida T, Tanaka H, Kuroda H, Shimizu J,
Horio Y, Sakao Y, Inaba Y, Iwata H, Hida T and Yatabe Y:
Standardized uptake value on (18)F-FDG-PET/CT is a predictor of
EGFR T790M mutation status in patients with acquired resistance to
EGFR-TKIs. Lung Cancer. 100:14–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee SM, Bae SK, Jung SJ and Kim CK: FDG
uptake in non-small cell lung cancer is not an independent
predictor of EGFR or KRAS mutation status: A retrospective analysis
of 206 patients. Clin Nucl Med. 40:950–958. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cho A, Hur J, Moon YW, Hong SR, Suh YJ,
Kim YJ, Im DJ, Hong YJ, Lee HJ, Kim YJ, et al: Correlation between
EGFR gene mutation, cytologic tumor markers, 18F-FDG
uptake in non-small cell lung cancer. BMC Cancer. 16:2242016.
View Article : Google Scholar
|
|
33
|
Ko KH, Hsu HH, Huang TW, Gao HW, Shen DH,
Chang WC, Hsu YC, Chang TH, Chu CM, Ho CL, et al: Value of
18F-FDG uptake on PET/CT and CEA level to predict
epidermal growth factor receptor mutations in pulmonary
adenocarcinoma. Eur J Nucl Med Mol Imaging. 41:1889–1897. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Putora PM, Früh M and Müller J: FDG-PET
SUV-max values do not correlate with epidermal growth factor
receptor mutation status in lung adenocarcinoma. Respirology.
18:734–735. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hogan A, Heyner S, Charron MJ, Copeland
NG, Gilbert DJ, Jenkins NA, Thorens B and Schultz GA: Glucose
transporter gene expression in early mouse embryos. Development.
113:363–372. 1991.PubMed/NCBI
|
|
36
|
Liemburg-Apers DC, Willems PH, Koopman WJ
and Grefte S: Interactions between mitochondrial reactive oxygen
species and cellular glucose metabolism. Arch Toxicol.
89:1209–1226. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fiorentini D, Prata C, Maraldi T, Zambonin
L, Bonsi L, Hakim G and Landi L: Contribution of reactive oxygen
species to the regulation of Glut1 in two hemopoietic cell lines
differing in cytokine sensitivity. Free Radic Biol Med.
37:1402–1411. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gorrini C, Harris IS and Mak TW:
Modulation of oxidative stress as an anticancer strategy. Nat Rev
Drug Discov. 12:931–947. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kawano Y, Iwama E, Tsuchihashi K,
Shibahara D, Harada T, Tanaka K, Nagano O, Saya H, Nakanishi Y and
Okamoto I: CD44 variant-dependent regulation of redox balance in
EGFR mutation-positive non-small cell lung cancer: A target for
treatment. Lung Cancer. 113:72–78. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jafari N, Kim H, Park R, Li L, Jang M,
Morris AJ, Park J and Huang C: CRISPR-Cas9 mediated NOX4 knockout
inhibits cell proliferation and invasion in HeLa cells. PLoS One.
12:e01703272017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Crosas-Molist E, Bertran E,
Rodriguez-Hernandez I, Herraiz C, Cantelli G, Fabra À, Sanz-Moreno
V and Fabregat I: The NADPH oxidase NOX4 represses epithelial to
amoeboid transition and efficient tumour dissemination. Oncogene.
36:3002–3014. 2017. View Article : Google Scholar :
|
|
42
|
Brunelle JK, Bell EL, Quesada NM,
Vercauteren K, Tiranti V, Zeviani M, Scarpulla RC and Chandel NS:
Oxygen sensing requires mitochondrial ROS but not oxidative
phosphorylation. Cell Metab. 1:409–414. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jung KH, Lee JH, Thien Quach CH, Paik JY,
Oh H, Park JW, Lee EJ, Moon SH and Lee KH: Resveratrol suppresses
cancer cell glucose uptake by targeting reactive oxygen
species-mediated hypoxia-inducible factor-1alpha activation. J Nucl
Med. 54:2161–2167. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Orcutt KP, Parsons AD, Sibenaller ZA,
Scarbrough PM, Zhu Y, Sobhakumari A, Wilke WW, Kalen AL, Goswami P,
Miller FJ Jr, et al: Erlotinib-mediated inhibition of EGFR
signaling induces metabolic oxidative stress through NOX4. Cancer
Res. 71:3932–3940. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sobhakumari A, Schickling BM, Love-Homan
L, Raeburn A, Fletcher EV, Case AJ, Domann FE, Miller FJ Jr and
Simons AL: NOX4 mediates cytoprotective autophagy induced by the
EGFR inhibitor erlotinib in head and neck cancer cells. Toxicol
Appl Pharmacol. 272:736–745. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhou Y, Yang Y, Yang C, Chen Y, Yang C, Du
Y, Zhao G, Guo Y, Ye L and Huang Y: Epidermal growth factor
receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of
Yunnan in southwestern China. Oncotarget. 8:15023–15033.
2017.PubMed/NCBI
|
|
47
|
Lan Q, He X, Shen M, Tian L, Liu LZ, Lai
H, Chen W, Berndt SI, Hosgood HD, Lee KM, et al: Variation in lung
cancer risk by smoky coal subtype in Xuanwei. China Int J Cancer.
123:2164–2169. 2008. View Article : Google Scholar
|
|
48
|
Mumford JL, He XZ, Chapman RS, Cao SR,
Harris DB, Li XM, Xian YL, Jiang WZ, Xu CW, Chuang JC, et al: Lung
cancer and indoor air pollution in Xuan Wei, China. Science.
235:217–220. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Pieper U, Eswar N, Davis FP, Braberg H,
Madhusudhan MS, Rossi A, Marti-Renom M, Karchin R, Webb BM, Eramian
D, et al: MODBASE: A database of annotated comparative protein
structure models and associated resources. Nucleic Acids Res.
34:D291–D295. 2006. View Article : Google Scholar :
|
